Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | NOS1 | P29475 | 3/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20272422 | 0.80 | SLC2A1 (0.47) | SLC2A1HTTPTK2MAPTNOS1 | |
| SCHEMBL10803369 | 0.77 | SLC2A1 (0.44) | SLC2A1HTTPTK2LMNAMAPT | |
| SCHEMBL6850410 | 0.77 | HTT (0.47) | SLC2A1HTTPTK2MAPTL3MBTL1 | |
| SCHEMBL9070472 | 0.76 | NOS1 (0.49) | SLC2A1HTTPTK2LMNAMAPT | |
| SCHEMBL10850431 | 0.74 | NT5E (0.42) | SLC2A1HTTPTK2NOS1DYRK1A | |
| SCHEMBL18879034 | 0.74 | SLC2A1 (0.56) | SLC2A1HTTPTK2MAPTL3MBTL1 | |
| SCHEMBL10805209 | 0.73 | SLC2A1 (0.64) | SLC2A1HTTLMNAMAPTPOLB | |
| SCHEMBL10803416 | 0.72 | SLC2A1 (0.70) | SLC2A1HTTLMNAMAPTPOLB | |
| SCHEMBL10847105 | 0.72 | GPR35 (0.41) | LMNANOS1 | |
| SCHEMBL24553744 | 0.71 | HTT (0.44) | SLC2A1HTTPTK2MAPTNOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376099-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | NOVARTIS AG (CH) | 2024-11-14 | — | — | US | disclosed |
| EP-4059934-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | Novartis AG (CH) | 2022-09-21 | — | — | EP | disclosed |
| US-20210101902-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | NOVARTIS AG (CH) | 2021-04-08 | — | — | US | disclosed |
| US-20210101902-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | NOVARTIS AG (CH) | 2021-04-08 | — | — | US | disclosed |
| US-10954233-B2 | Compounds and compositions as inhibitors of endosomal toll-like receptors | NOVARTIS AG (CH) | 2021-03-23 | — | — | US | disclosed |
| US-10954233-B2 | Compounds and compositions as inhibitors of endosomal toll-like receptors | NOVARTIS AG (CH) | 2021-03-23 | — | — | US | disclosed |
| US-20190211009-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. | 2019-07-11 | — | — | US | disclosed |
| US-20190211009-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. | 2019-07-11 | — | — | US | disclosed |
| WO-2018047081-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | NOVARTIS AG (CH) | 2018-03-15 | — | — | WO | disclosed |
| US-7652035-B2 | CRF receptor antagonists and methods relating thereto | Neurocrine Bioscience, Inc. (US) | 2010-01-26 | — | — | US | disclosed |
| US-4833136-A | ANTIINFLAMMATORY AGENTS | BEECHAM GROUP P.L.C. (GB) | 1989-05-23 | — | — | US | disclosed |
| US-4818754-A | ANTIALLERGENS | BEECHAM GROUP P.L.C. OF BEECHAM HOUSE (GB) | 1989-04-04 | — | — | US | disclosed |
| EP-0243055-A2 | Pyrazolopyridine derivatives, process for their preparation, and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1987-10-28 | — | — | EP | disclosed |
| EP-0119774-B1 | ANTI-INFLAMMATORY PYRAZOLO PYRIDINES | BEECHAM GROUP PLC (GB) | 1987-06-24 | — | — | EP | disclosed |
| US-4670432-A | Pyrazolopyridine derivatives useful in treating inflammation and allergic conditions | BEECHAM GROUP P.L.C. (GB) | 1987-06-02 | — | — | US | disclosed |
| US-4576952-A | Pyrazolopyridine derivatives and their use as anti-inflammatory and/or anti-allergic agents | BEECHAM GROUP P.L.C. (GB) | 1986-03-18 | — | — | US | disclosed |
| US-4559348-A | SKIN DISORDERS | BEECHAM GROUP, P.L.C. (GB) | 1985-12-17 | — | — | US | disclosed |
| EP-0152910-A2 | pyrazolopyridine derivatives | BEECHAM GROUP PLC (GB) | 1985-08-28 | — | — | EP | disclosed |
| EP-0151962-A2 | Pyrazolopyridine derivatives | BEECHAM GROUP PLC (GB) | 1985-08-21 | — | — | EP | disclosed |
| EP-0119774-A1 | Anti-inflammatory pyrazolo pyridines | BEECHAM GROUP PLC (GB) | 1984-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376099-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | TLR3, TLR1, TLR4 | SLC2A1 3940/4885HTT 4068/4885PTK2 2619/4885 |
| US-20210101902-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | TLR3, TLR1, TLR4 | SLC2A1 3940/4885HTT 4068/4885PTK2 2619/4885 |
| US-20190211009-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | TLR3, TLR1, TLR4 | SLC2A1 3940/4885HTT 4068/4885PTK2 2619/4885 |
| US-10954233-B2 | Compounds and compositions as inhibitors of endosomal toll-like receptors | TLR3, TLR1, TLR4 | SLC2A1 3940/4885HTT 4068/4885PTK2 2619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.